Omayra Salgado Melendez, | |
Calle Bolivia #60, Hato Rey, PR 00910-9175 | |
(787) 767-9600 | |
Not Available |
Full Name | Omayra Salgado Melendez |
---|---|
Gender | Female |
Speciality | Counselor - Addiction (substance Use Disorder) |
Location | Calle Bolivia #60, Hato Rey, Puerto Rico |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912167362 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Omayra Salgado Melendez, Parcelas Quebrada Seca #6097, Ceiba, PR 00735-3504 Ph: (787) 502-2036 | Omayra Salgado Melendez, Calle Bolivia #60, Hato Rey, PR 00910-9175 Ph: (787) 767-9600 |
News Archive
As autumn approaches and millions of Americans consider taking an H1N1 Swine Flu vaccination, the integrity of all vaccine developers has been called into question by the financial relationship of a leading vaccine advocate and a pharmaceutical manufacturer. Dr. Paul Offit of Children's Hospital of Philadelphia (CHOP), who was interviewed for a Dateline NBC television special, failed to tell millions of viewers that while he was promoting MMR as safe he had also made tens of millions of dollars from selling another vaccine patent to Merck, which is the manufacturer of MMR.
The Translational Genomics Research Institute, an affiliate of City of Hope, The Pathogen and Microbiome Institute at Northern Arizona University and the Ecology and Evolutionary Biology Department at the University of Arizona have formed a union dedicated to tracking the COVID-19 coronavirus, it was announced today.
The study "Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19" was recently published on the preprint medRxiv* server.
Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full scale production by Lonza under a separate agreement announced in 2009.
› Verified 9 days ago
Waleska Perez, Counselor Medicare: Not Enrolled in Medicare Practice Location: #435 Hostos Ave., Hato Rey, PR 00918 Phone: 787-995-2700 Fax: 787-995-2706 | |
Dr. Carlos A. Garcia Rodriguez, PH.D. Counselor Medicare: Not Enrolled in Medicare Practice Location: Hostos Ave. 431, Hato Rey, PR 00918 Phone: 787-753-9515 Fax: 787-753-9515 | |
Andres Raul Andino, Counselor Medicare: Not Enrolled in Medicare Practice Location: 128 Ave Roosevelt, Hato Rey, PR 00917 Phone: 787-220-1272 |